{
  "id": 1685980,
  "title": "BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries",
  "url": "https://urgent.news/2026/08/18/beone-medicines-beone-care-foundation-and-the-max-foundation-renew",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T10:09:39.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-medicines-beone-care-foundation-and-the-max-foundation-renew-partnership-to-expand-access-to-brukinsa-for-the-treatment-of-chronic-lymphocytic-leukemia-in-low-and-middle-income-countrie"
  },
  "original_language": "en",
  "account": null,
  "summary": "Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE — BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}